select trial semaglutide nejm SELECT Trial: Semaglutide 2.4 mg

SKU: 19524514628

Pay in 4 interest-free payments of $6.36 Learn more

Live Spec

SELECT Trial: Semaglutide 2.4 mg Cuts Cardiovascular Risk in Obesity (NEJM 2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes New England Journal of Medicine Semaglutide in Patients with Obesity Related Heart Failure and Type 2 Diabetes New England Journal of Medicine In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results SELECT trial was published today in NEJM. Below, I summarize the trial and the drug in this thread. Dr Shailesh Singh Rattibha In the SURMOUNT 5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide in reducing body weight and waist circumference. Full trial results and Research Summary

Store: globalkontent.com · Domain: globalkontent.com